{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:03:56Z","timestamp":1791947036876,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"German Research Council","award":["Project No. 413657723"],"award-info":[{"award-number":["Project No. 413657723"]}]},{"name":"Medical Faculty of Halle University","award":["No. CS22\/06"],"award-info":[{"award-number":["No. CS22\/06"]}]},{"DOI":"10.13039\/100030902","name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030902","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to assess the prognostic value of serum \u03b2-synuclein (\u03b2-syn), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in patients with moderate-to-severe acute ischemic stroke. We measured \u03b2-syn, GFAP and NfL in serum samples collected one day after admission in 30 adult patients with moderate-to-severe ischemic stroke due to middle cerebral artery (MCA) occlusion. We tested the associations between biomarker levels and clinical and radiological scores (National Institute of Health Stroke Scale scores, NIHSS, and Alberta Stroke Program Early CT Score, ASPECTS), as well as measures of functional outcome (modified Rankin Scale, mRS). Serum biomarkers were significantly associated with ASPECTS values (\u03b2-syn p\u2009=\u20090.0011, GFAP p\u2009=\u20090.0002) but not with NIHSS scores at admission. Patients who received mechanical thrombectomy and intravenous thrombolysis showed lower \u03b2-syn (p\u2009=\u20090.029) und NfL concentrations (p\u2009=\u20090.0024) compared to patients who received only mechanical thrombectomy. According to median biomarker levels, patients with high \u03b2-syn, NfL or GFAP levels showed, after therapy, lower clinical improvement (i.e., lower 24-h NIHSS change), higher NIHSS scores during hospitalization and higher mRS scores at 3-month follow-up. Elevated serum concentrations of \u03b2-syn (p\u2009=\u20090.016), NfL (p\u2009=\u20090.020) or GFAP (p\u2009=\u20090.010) were significantly associated with 3-month mRS of 3\u20136 vs. 0\u20132 even after accounting for age, sex and renal function. In patients with moderate-to-severe acute ischemic stroke, serum \u03b2-syn, NfL and GFAP levels associated with clinical and radiological scores at different timepoints and were able to predict short- and middle-term clinical outcomes.<\/jats:p>","DOI":"10.1038\/s41598-023-47765-7","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T10:02:25Z","timestamp":1701165745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Serum \u03b2-synuclein, neurofilament light chain and glial fibrillary acidic protein as prognostic biomarkers in moderate-to-severe acute ischemic stroke"],"prefix":"10.1038","volume":"13","author":[{"given":"Lorenzo","family":"Barba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Vollmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Abu-Rumeileh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Halbgebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Oeckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Steinacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Kollikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Schuhmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter U.","family":"Heuschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Georg","family":"Haeusler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Neugebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"47765_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1161\/STROKEAHA.120.029232","volume":"52","author":"FA Montellano","year":"2021","unstructured":"Montellano, F. A. et al. Role of blood-based biomarkers in ischemic stroke prognosis: A systematic review. Stroke 52, 543\u2013551. https:\/\/doi.org\/10.1161\/STROKEAHA.120.029232 (2021).","journal-title":"Stroke"},{"key":"47765_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak, A. et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat. Rev. Neurol. 18, 158\u2013172 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"47765_CR3","doi-asserted-by":"publisher","first-page":"E1338","DOI":"10.1212\/WNL.0000000000006282","volume":"91","author":"S Tiedt","year":"2018","unstructured":"Tiedt, S. et al. Serum neurofilament light a biomarker of neuroaxonal injury after ischemic stroke. Neurology 91, E1338\u2013E1347 (2018).","journal-title":"Neurology"},{"key":"47765_CR4","doi-asserted-by":"publisher","first-page":"eaay1913","DOI":"10.1126\/scitranslmed.aay1913","volume":"12","author":"TF Gendron","year":"2020","unstructured":"Gendron, T. F. et al. Plasma neurofilament light predicts mortality in patients with stroke. Sci. Transl. Med. 12, eaay1913 (2020).","journal-title":"Sci. Transl. Med."},{"key":"47765_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12974-021-02254-4","volume":"18","author":"CH Chen","year":"2021","unstructured":"Chen, C. H. et al. Plasma neurofilament light chain level predicts outcomes in stroke patients receiving endovascular thrombectomy. J. Neuroinflamm. 18, 195 (2021).","journal-title":"J. Neuroinflamm."},{"key":"47765_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/mds.28941","volume":"37","author":"L Barba","year":"2022","unstructured":"Barba, L. et al. Alpha and beta synucleins: From pathophysiology to clinical application as biomarkers. Mov Disord. 37, 669\u2013683 (2022).","journal-title":"Mov Disord."},{"key":"47765_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/jnnp-2020-324306","volume":"92","author":"S Halbgebauer","year":"2021","unstructured":"Halbgebauer, S. et al. Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry 92, 349\u2013356 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"47765_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/ALZ.12790","author":"P Oeckl","year":"2022","unstructured":"Oeckl, P. et al. Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. Alzheimers Dement. https:\/\/doi.org\/10.1002\/ALZ.12790 (2022).","journal-title":"Alzheimers Dement."},{"key":"47765_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207371","author":"L Barba","year":"2023","unstructured":"Barba, L. et al. CSF synaptic biomarkers in AT(N)-based subgroups of lewy body disease. Neurology https:\/\/doi.org\/10.1212\/WNL.0000000000207371 (2023).","journal-title":"Neurology"},{"key":"47765_CR10","doi-asserted-by":"publisher","first-page":"9639","DOI":"10.3390\/ijms23179639","volume":"23","author":"R Halbgebauer","year":"2022","unstructured":"Halbgebauer, R. et al. Neurochemical monitoring of traumatic brain injury by the combined analysis of plasma beta-synuclein, NfL, and GFAP in polytraumatized patients. Int. J. Mol. Sci. 23, 9639 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"47765_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/cells12020288","volume":"12","author":"A Haarmann","year":"2023","unstructured":"Haarmann, A. et al. Vasoactive soluble endoglin: A novel biomarker indicative of reperfusion after cerebral large-vessel occlusion. Cells 12, 288 (2023).","journal-title":"Cells"},{"key":"47765_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/neurintsurg-2020-017155","volume":"14","author":"AM Kollikowski","year":"2022","unstructured":"Kollikowski, A. M. et al. Progression of cerebral infarction before and after thrombectomy is modified by prehospital pathways. J. Neurointerv. Surg. 14, 485\u2013489 (2022).","journal-title":"J. Neurointerv. Surg."},{"key":"47765_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00234-020-02576-9","volume":"63","author":"RR Leker","year":"2021","unstructured":"Leker, R. R. et al. Post-stroke ASPECTS predicts outcome after thrombectomy. Neuroradiology 63, 769\u2013775 (2021).","journal-title":"Neuroradiology"},{"key":"47765_CR14","doi-asserted-by":"publisher","first-page":"E1434","DOI":"10.1212\/WNL.0000000000200002","volume":"98","author":"S Halbgebauer","year":"2022","unstructured":"Halbgebauer, S. et al. Blood \u03b2-synuclein and neurofilament light chain during the course of prion disease. Neurology 98, E1434\u2013E1445 (2022).","journal-title":"Neurology"},{"key":"47765_CR15","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1161\/STROKEAHA.120.032487","volume":"52","author":"EA Mistry","year":"2021","unstructured":"Mistry, E. A. et al. Predicting 90-day outcome after thrombectomy: Baseline-adjusted 24-hour NIHSS is more powerful than NIHSS score change. Stroke 52, 2547\u20132553 (2021).","journal-title":"Stroke"},{"key":"47765_CR16","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1161\/STROKEAHA.120.032487","volume":"52","author":"HP Mistry","year":"2021","unstructured":"Mistry, H. P. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 52, 2547\u20132553 (2021).","journal-title":"Stroke"},{"key":"47765_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/ene.13554","volume":"25","author":"GM De Marchis","year":"2018","unstructured":"De Marchis, G. M. et al. Serum neurofilament light chain in patients with acute cerebrovascular events. Eur. J. Neurol. 25, 562\u2013568 (2018).","journal-title":"Eur. J. Neurol."},{"key":"47765_CR18","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-021-10704-5","volume":"269","author":"PP Deng","year":"2022","unstructured":"Deng, P. P. et al. NIHSS-the Alberta Stroke Program Early CT Score mismatch in guiding thrombolysis in patients with acute ischemic stroke. J. Neurol. 269, 1515\u20131521 (2022).","journal-title":"J. Neurol."},{"key":"47765_CR19","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/ene.15273","volume":"29","author":"M Correia","year":"2022","unstructured":"Correia, M. et al. Early plasma biomarker dynamic profiles are associated with acute ischemic stroke outcomes. Eur. J. Neurol. 29, 1630\u20131642 (2022).","journal-title":"Eur. J. Neurol."},{"key":"47765_CR20","doi-asserted-by":"publisher","first-page":"118063","DOI":"10.1016\/j.jns.2021.118063","volume":"429","author":"J rahmig","year":"2021","unstructured":"rahmig, J. et al. Serum neurofilament light chain levels are associated with stroke severity and functional outcome in patients undergoing endovascular therapy for large vessel occlusion. J. Neurol. Sci. 429, 118063 (2021).","journal-title":"J. Neurol. Sci."},{"key":"47765_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-021-01915-8","volume":"19","author":"N R\u00fcbsamen","year":"2021","unstructured":"R\u00fcbsamen, N. et al. Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population: An analysis from the MEMO study. BMC Med. 19, 1\u201310 (2021).","journal-title":"BMC Med."},{"key":"47765_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/BRAIN\/AWAC328","author":"S Abu-Rumeileh","year":"2022","unstructured":"Abu-Rumeileh, S. et al. The multifaceted role of neurofilament light chain protein in non-primary neurological diseases. Brain https:\/\/doi.org\/10.1093\/BRAIN\/AWAC328 (2022).","journal-title":"Brain"},{"key":"47765_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1161\/STROKEAHA.120.032787","volume":"53","author":"JC de Jonge","year":"2022","unstructured":"de Jonge, J. C. et al. Temporal profile of pneumonia after stroke. Stroke 53, 53\u201360 (2022).","journal-title":"Stroke"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47765-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47765-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47765-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T11:13:03Z","timestamp":1701169983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47765-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["47765"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-47765-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KGH reports speaker\u00b4s honoraria, consulting fees, lecture honoraria and\/or study grants from Abbott, Alexion, Amarin, AstraZeneca, Bayer Healthcare, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Medronic, Pfizer, Portola, Premier Research, Sanofi, SUN Pharma, and W.L. Gore & Associates. M. Otto gave scientific advice for Fujirebio, Roche, Biogen, and Axon; the foundation of the state Baden-Wuerttemberg handed in a patent for the measurement of beta-synuclein and relevant authors are M. Otto, S. Halbgebauer, and P. Oeckl. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20941"}}